Where do we go from here?

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue SUPPL. 1, 2009, Pages

  Pizzo, Philip A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Empirical therapy; Fever; Monotherapy; Neutropenia

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BLOOD DISEASE; HUMAN; NEUTROPENIA; PYREXIA IDIOPATHICA; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HUMANS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84866456102     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp076     Document Type: Article

References (8)

1. De Pauw BE, Kauw F, Muytjens H et al. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983; 12 Suppl A: 93-9.
2. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
3. De Pauw BE, Deresinski SC, Feld R et al. Ceftazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med 1994; 120: 834-44.
4. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
5. Feld R, De Pauw B, Berhman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-8.
6. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-11.
7. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341: 893-900.
8. De Pauw BE, Rubin RH. Empiric versus pre-emptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transpl Infect Dis 2006; 8: 1-2.